Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019

Recent evidence has emerged concerning delayed cutaneous hypersensitivity reactions after infliximab or adalimumab applications in patients with coronavirus disease 2019 (COVID‐19). A few real‐world studies compared the events, clinical features, and prognosis of infliximab‐ or adalimumab‐related delayed cutaneous hypersensitivity reactions in COVID‐19 patients. Disproportionality analysis and Bayesian analysis were utilized to determine the suspected adverse events of delayed cutaneous hypersensitivity reactions after infliximab or adalimumab use based on the Food and Drug Administration's Adverse Event Reporting Systems (FAERS) from May 2020 to December 2021. Additionally, the times to onset and fatality rates of delayed cutaneous hypersensitivity reactions following infliximab or adalimumab were compared. In total, 475 reports of delayed cutaneous hypersensitivity reactions were associated with infliximab or adalimumab. Females were affected almost twice more than males. Among the two therapies, infliximab had the highest association with delayed cutaneous hypersensitivity reactions based on the highest reporting odds ratio (2.14, 95% two‐sided confidence interval [CI] = 1.2–3.81), proportional reporting ratio (1.95, χ (2) = 7.03), and empirical Bayesian geometric mean (1.94, 95% one‐sided CI = 1.2). Infliximab‐related delayed cutaneous hypersensitivity reactions had earlier onset (0 [interquartile range (IQR): 0–0] days vs. 166.5 (IQR: 18–889.5) days, p < 0.05), while adalimumab‐related delayed cutaneous hypersensitivity reactions have higher fatality rate (0.44% vs. 0.00%). Based on the FAERS database, we profiled delayed cutaneous hypersensitivity reactions related to infliximab or adalimumab application in patients with COVID‐19 with more points of occurrences, clinical characteristics, and prognosis.